|
|
Peregrine's Phosphatidylserine-Based Vascular Targeting Agent Technology Presented At Angiogenesis Conference.
- Article from:
-
PR Newswire
- Article date:
-
September 30, 2003
|
Copyright informationCOPYRIGHT 2003 PR Newswire Association, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TUSTIN, Calif., Sept. 30 /PRNewswire/ -- Peregrine Pharmaceuticals today presented pre-clinical data highlighting phosphatidylserine (PS) as a potential treatment for cancer. The talk, titled "Antibodies to Phospholipids as Vascular Targeting Agents for Cancer Treatment," was presented at the Angiogenesis: New Opportunities & Solutions for Drug Development conference in Cambridge, MA by Peregrine's President and CEO Steven King.
"We are pleased by this opportunity to present pre-clinical data related to our anti-PS antibody clinical candidate for use as a direct anti-cancer agent and as a potential targeting agent for our Vascular Targeting Agent (VTA) technology ...